About: http://data.cimple.eu/news-article/e4be414eec7483bad72e08cbd35ccc7521d282351390b3c3cd31734d

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/e4be414eec7483bad72e08cbd35ccc7521d282351390b3c3cd31734d Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pharmaceutical company AstraZeneca said Tuesday it had "voluntarily paused" a randomized clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness. The company, which is developing the drug alongside the University of Oxford, is a frontrunner in the global race for a Covid-19 vaccine. "As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials." It added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. "We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson added. It was not immediately clear where the patient was, or the nature and severity of their illness. Holds during clinical trials are not uncommon, but this is thought to be the first time it has happened for a Covid-19 vaccine trial. AstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates. In the US, the company began enrolling 30,000 volunteers across dozens of sites on August 31. The vaccine, called AZD1222, uses a weakened version of a common cold causing adenovirus that has been engineered to code for the spike protein that the novel coronavirus uses to invade cells. After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected. ia/bfm
schema:headline	AstraZeneca pauses Covid-19 vaccine trial after unexplained illness
schema:mentions	Adenoviridae Pharmaceutical industry Common cold Protein Ia (cuneiform) University of Oxford Immune system AstraZeneca Vaccine Coronavirus Coronavirus disease 2019 Randomized controlled trial Radio in New Zealand
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-09-08 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	81 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 942 MB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software